Health knowledge made personal
WellPage for Raloxifene
+ Bookmark › Share
Search posts:

Raloxifene - Articles

Breast Cancer Prevention: Tamoxifen vs. Raloxifene by Aaron Tabor Medical Doctor Posted Wed 21 Apr 2010 6:29am The ultimate goal in breast cancer research (or any disease research) is to find a way to prevent breast cancer from occurring.  Tamoxifen is widely used to treat breast cancer patients with estrogen receptor - positive breast cancer; however, it has also been approved since 1998 to help prevent breast cancer in high risk breast cancer patients.  ... Read on »
Study:Osteoporosis Drug Raloxifene Shown to be as Effective as Tamoxifen in Preventing Invasive Bre by Dr. Jennifer Berman Medical Doctor Posted Sat 13 Sep 2008 4:31am (April 17, 2006)--Initial results of the Study of Tamoxifen and Raloxifene, or STAR, show that the drug raloxifene, currently used to prevent and treat osteoporosis in postmenopausal women, works as well as tamoxifen in reducing breast cancer risk for postmenopausal women at increased risk of the disease. (April 17, 2006)--Initial results of the ... Read on »
raloxifene and cognition by Neurodoc .. Patient Expert Posted Sat 29 Sep 2012 4:21pm OBJECTIVE:: The aim of this study was to examine the effects of raloxifene compared with those of placebo on verbal memory, mental processing speed, depression, anxiety, and quality of life. METHODS:: A randomized, double-blind, placebo-controlled trial of 213 healthy women 70 years or older was conducted between July 2003 ... Read on »
PAL memberBreast Cancer Actionis ... by Prescription Access Litigation Patient ExpertHealth Maven Posted Thu 30 Oct 2008 3:21pm PAL member Breast Cancer Action issued the following statement yesterday. This raises some important issues — about the use of prescription drugs to prevent cancer, about the environmental vs. individual factors in disease, and about how to deal with serious illnesses like cancer — especially whether to emphasize prevention vs. treatment, and ... Read on »
Breast Cancer Genetics: The Role of Your Family Physician Part 2 by Alvin B. Lin Medical DoctorHealth Maven Posted Mon 20 May 2013 5:00am So now that the furor over Angelina Jolie's disclosure has died down, I thought I'd take a closer look at the US Preventive Services Task Force evidence review published last month in Annals of Internal Medicine in which they concluded that selective estrogen receptor modulators can reduce the risk of breast cancer.  However, if you'll reca ... Read on »
Breast Cancer Breakthrough by Linda MacDonald Glenn Healthy Living ProfessionalHealth Maven Posted Wed 01 Oct 2008 10:28pm 1 Comment Good news for women: A large government sponsored study of nearly 20,000 postmenopausal women found that raloxifene (marketed under the name of Evista) reduces their chance of developing breast cancer as effectively as tamoxifen, the only drug previously shown to reduce the risk, but is less likely to cause serious side effects such as uterine ca ... Read on »
AnFDAadv ... by Medical Quack Patient ExpertHealth Maven Posted Mon 10 Nov 2008 4:24pm   An FDA advisory panel on Tuesday voted in favor of recommending that Eli Lilly's bone-strengthening drug raloxifene, sold under the brand-name Evista, be approved to reduce the risk of breast cancer in some women, the Wall Street Journal reports (Corbett Dooren, Wall Street Journal, 7/25). FDA in 1997 approved Evista to help prevent o ... Read on »
Postmenopausal Hormone Therapy That Reduces Breast Cancer Risk? by Aaron Tabor Medical Doctor Posted Thu 22 Oct 2009 12:00am New research presented October 19, 2009 at the annual meeting of the American Society for Reproductive Medicine suggests that we might one day actually have a postmenopausal hormone therapy that reduces breast cancer risk. A team of researchers from Yale University, the Federal University of Parana (Brazil), and Wyeth Research examined the ... Read on »
Cancellation of a Clinical Trial: Has An Injustice Been Done to Women? by Linda MacDonald Glenn Healthy Living ProfessionalHealth Maven Posted Tue 26 Aug 2008 4:26pm The Wall Street Journal on Tuesday examined the reasoning behind the National Cancer Institute 's decision in June to cancel a five-year, $100 million study designed to test the new class of breast cancer prevention drugs known as aromatase inhibitors. The trials were to be conducted by the Pittsburgh, Pa.-based National Surgical Adjuvant Breast ... Read on »